<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Feb. 5, 2020 (HealthDay News) — Among children at risk for asthma, prenatal vitamin D supplementation does not affect the incidence of asthma or recurrent wheeze at age 6, according to a study published in the Feb. 6 issue of the New England Journal of Medicine<\/i>.<\/p>\n
Augusto A. Litonjua, M.D., M.P.H., from the University of Rochester Medical Center in New York, and colleagues followed children enrolled in a trial of prenatal vitamin D supplementation to prevent asthma and recurrent wheeze in young children from age 3 to 6 years. The impact of maternal vitamin D supplementation during pregnancy (mothers received either 4,400 IU [vitamin D group] or 400 IU [control group] of vitamin D3<\/sub> per day) was examined on the incidence of asthma and recurrent wheeze at age 6 years.<\/p>\n The researchers found that in neither the intention-to-treat analysis nor an analysis with stratification according to the maternal 25-hydroxyvitamin D level during pregnancy was there an effect of maternal vitamin D supplementation on asthma and recurrent wheeze. Vitamin D supplementation also had no effect on most of the prespecified secondary outcomes. A very small effect on airway resistance was seen, as measured by impulse oscillometry, although the significance of this finding was uncertain.<\/p>\n “The effect of prenatal supplementation on airway resistance through the age of 6 years suggests that there may be prenatal programming of lung airways, but these small effects will need to be validated in future studies,” the authors write.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n